Share on LinkedInShare on LinkedIn

ARTICLE · 25 MAY 2012

IP Bulletin - May 2012

Charles Russell Speechlys LLP
Charles Russell Speechlys LLP
Contributor
Charles Russell Speechlys LLP

Charles Russell Speechlys LLP

Charles Russell Speechlys is an international law firm with a focus on private capital, at the...

View firm profile
Explore more from Charles Russell Speechlys LLP

The High Court has granted an interim injunction restraining sale of Teva's generic efavirenz product pending trial, in order to prevent patent infringement.

United KingdomIntellectual Property

RECENT DEVELOPMENTS

PATENTS

High Court refuses to strike out an application for an injunction against infringing a drug patent

Merck Sharp & Dohme Corp and another v Teva Pharma BV and another, 15 March 2012.

The High Court has granted an interim injunction restraining sale of Teva's generic efavirenz product pending trial, in order to prevent patent infringement. The marketing authorisation for the generic product was applied for much earlier than normal before the expiry of the relevant patent and Teva refused to answer questions about the product launch. The case makes clear that a record of behaviour of a generic company (including the early launch of another generic product) is likely to be taken into account by the court when an application for an Interim injunction is made.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from